Biosimilars in chronic inflammatory diseases: facts and remaining questions 5 years after their introduction in Europe.

Biosimilars have democratized access to powerful medicines. Efficacy and safety studies provided reassuring data, but knowledge gaps persist. The availability of so-called 'bio-betters' might open new avenues and change clinical practice.